A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
Clinical trial NCT05394012 · UNKNOWN
Trial details
- NCT number
- NCT05394012
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2023-02-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.